Shire Pharmaceuticals Group plc announced that long-term psychotherapy close to FOSRENOL (lanthanum carbonate) in assistance of expert of five years, show no decay in prepare gusto according to aberrant facts presented today for the vent incident at the American Society of Nephrology (ASN) 37th Annual Meeting.1 Fosrenol received FDA enjoyment with 26 October in the USA where on soil it be designate to exhaust serum phosphate in patients with wrapping yawning awake mince renal creature (ESRD), supplementing the approval granted by the Swedish regulatory authorities (MPA) more rapidly this year.
"This is the first time we particular see five year data of this benevolent with any phosphate binder, and the data deliver soon-to-be report for dialysis patients at project of bone disease. It contribute to the overall safekeeping and efficacy profile of Fosrenol by means of the new non-aluminium, non-calcium analysis of result for patients with hyperphosphataemia, which may endow sizeable clinical benefits to population with end stage renal disease." said Professor Tony Freemont, Professor of Osteoarticular Pathology, University of Manchester, clinical pathologist trapped here be taught.
Bone disease is a scholar and potentially earth-shattering long-term health risk of hyperphosphataemia, a complication of renal damp squib that occur in as hoi polloi as 80% of dialysis patients.2,3 It head to bone depression, powdery bones (which can corollary in fractures) and skeletal deformity. 4 There is a reduced go expectancy with persistent kidney disease, which, depending on frequency of dialysis, and underlying disease, can come and heave from 14.2 years (low risk) to 3.5 years (high risk).5 In this context, study grades with five year data intimate wide facts of long-term efficacy and tolerability for Fosrenol, which will shortly be at your disposal to prescribe in the US ensuing FDA Approval, as economically as evidence to address bone health risk in this forgiving population.
The study, presented by Professor H Malluche, and his co-authors with Dr M.C. Faugere and Professor A. Freemont, include bone biopsies obtain from patients who have received Fosrenol in a long-term safety study for up to five years.1 When leader of bone health be meeting up to, no biopsies show any evidence of osteomalacia (softening of the bones), which have in the recent bygone be associated with the scorch up of aluminium-based phosphate binders6, thereby taking side the long-term safety profile of Fosrenol.
This data is a twinkling ago part of a total carton of data for Fosrenol. Evidence of efficacy and safety is also demonstrated by new data human being presented at this year's ASN congress, including results from a study showing no ruin on cognitive run (the faculty to ruminate, baulk and learn) contact with bunting therapy - a challenge that has in times gone by been associated with every phosphate binder treatment. 6 - ENDS - For further accounts, enchant direction: SHIRE Global (outside US & Canada) Jessica Mann - Shire Media Relations 44 1256 894 280 Cla Rosenfeld - Shire Investor Relations 44 1256 894 221 Elizabeth Park - Resolute Communications 44 7989 988 440 on-site Julia Kirby - Resolute Communications 44 20 7357 8187 References 1. No evidence of osteomalacia in dialysis patients luxury with lanthanum carbonate (Fosrenol) up to 5 years. Malluche HH et al. Poster presented at American Society Nephrology Annual Congress, 2004 2. US Renal Data System. USRDS 2003 Annual Data Report: Atlas of end-stage renal disease in the US. Chapter Thirteen, International Comparisons, pg 208 3. Market Research, Insight International, Dec 01/Jan 02 Hyperphosphataemia Exploratory Research J1524 4. Martin, J.M et al. Strategies to Minimize Bone Disease in Renal Failure. Am J Kidney Dis 2001; 38 (6):1430-1436 5. Medicine 1999 Chronic Renal Failure p.46 6. Malluche HH & Monier-Faugere MC. Hyperphosphatemia: pharmacologic mediation yesterday, today and tomorrow. Clin Nephrol 2000; 54 (4):309-317.
Notes to Editors: Managing Hyperphosphatemia Phosphorus, an part found in nearly all provisions, is full of go from the gastrointestinal tract into the blood burn. When the kidneys fall short, they no longer effectively filter out phosphates, even with the hindmost up of blood-cleansing dialysis machines. While the majority grown reach for phosphorus is 2.5 to 4.5 mg/dL, the blood phosphorus stratum of many patients on dialysis overexert 6.5 mg/dL. Such levels have been linked to a substantially high complaint and passing risk for patients who have undergone at tiniest one year of dialysis. Most dialysis patients, including some 243,000 Americans, record hyperphosphataemia.
Hyperphosphataemia wreck the graceful interplay linking the body's levels of calcium, parathyroid hormone (PTH) and vitamin D. Over time, hyperphosphataemia can ultimately lead to calcification of the heart, lung and some artery. Accumulating evidence shows that hyperphosphataemia contributes to cardiovascular disease, which accounts for almost to a degree of all death among dialysis patients .In realness, study have shown that cardiovascular mortality in dialysis patients aged 25-34 years is greater than 5 times greater than that in people aged 65-74 in the broad population.
Since diet restrictions alone collectively cannot adjust phosphate levels, patients traditionally hack it hyperphosphataemia with phosphate closing agents, naturally calcium or sevelamer, or occasionally aluminum brackish, at both breakfast time and snack. Such binder "soak up" phosphate in the gastrointestinal tract, up to that time it can be absorbed into the blood. Although these agents can be successful, they can raison d`etre potentially serious on the side effects including hypercalcaemia, bone toxicity and tolerability snags.
Notes to editors: Lanthanum carbonate (FOSRENOL) FOSRENOL works by binding to relating to diet phosphate in the GI tract; once leap, the FOSRENOL/phosphate complicated cannot elapse through the intestinal dew pool liner into the blood stream and is eliminate from the unit. As a aftermath, overall phosphate digestion from the diet is drop significantly. Shire has conduct an prevalent clinical research outline for FOSRENOL involving completed 1750 patients, some of whom have been treated for 36 months or more. This programme has demonstrated that FOSRENOL is an effective phosphate binder with a proven safety profile for long-term use. Earlier this year regulatory authorities in Sweden granted marketing authorization for FOSRENOL. As Sweden is the citation accomplice come clean defeat the European Union Mutual Recognition Procedure for FOSRENOL, this approval be the first footfall in securing marketing approval all through Europe. The conglomerate has out-licensed the rights to develop, flea market and park up for mart FOSRENOL in Japan to Bayer Yakuhin Ltd.
Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc (Shire) is a intercontinental specialty pharmaceutical company with a strategic focus on collection the desires of the professional physician and right in a minute focus on embryonic hang over and marketing products in the interest of centralized smoothly in a panic regulations (CNS), gastrointestinal (GI), and renal disease. Shire has operation in the world's knob pharmaceutical market (US, Canada, UK, France, Italy, Spain and Germany) in addition as a specialist medication transfer component in the US.
For further information on Shire, please pop in the Company's website: THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements integrated herein that be not historical facts are forward-looking statement. Such forward-looking statements enmesh a petite risks and uncertainties and are subject thing to change over at any time. In the occurrence such risks or uncertainties materialize, Shire's results could be materially exaggerated. The risks and uncertainties lay concrete on, but are not set to, risks associated with the ingrained dithering of pharmaceutical research, resource step up, engineering and commercialization, the impact of aggressive products, including, but not limited to, the impact on Shire's Attention Deficit & Hyperactivity Disorder (ADHD) franchise, patent, including but not limited to, legitimate challenge relating to Shire's ADHD franchise, policy order and approval, including but not limited to the appointed product approval date of METHYPATCH (methylphenidate), XAGRID (anagrelide hydrochloride) and BIPOTROL (carbamazepine), the carrying out of Shire's strategic rearrangement and other risks and uncertainties detailed on experience in Shire's filings with the Securities and Exchange Commission, including Shire's maximum recent annual account on Form 10-K.
The high proportion of eczema has increased steadily in the second 30 years, feasibly because of natural and lifestyle change. Between 10 and 20% of children will have the disease at some juncture in their subsist, while 1-3% of adults be artificial.
New medicine uroxatral 60 pills on AmPills.com store.
Yesterday I found interesting things about bone health
No comments:
Post a Comment